B010-A / Shanghai Pharma - LARVOL DELTA

B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: Tongji University | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2022 ➔ Sep 2024 | Trial primary completion date: Aug 2022 ➔ Aug 2024

Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=3 | Recruiting | Sponsor: Tongji University | Trial primary completion date: May 2022 ➔ Aug 2022

Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Lung Cancer • Oncology • Solid Tumor • CRP • GPC3